You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

CLINICAL TRIALS PROFILE FOR CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Canagliflozin; Metformin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00968812 ↗ CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride Completed Janssen Research & Development, LLC Phase 3 2009-09-01 The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin.
NCT01081834 ↗ The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial Completed Janssen Research & Development, LLC Phase 3 2010-03-01 The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise.
NCT01106625 ↗ The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea) Completed Janssen Research & Development, LLC Phase 3 2010-05-01 The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
NCT01106677 ↗ The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial) Completed Janssen Research & Development, LLC Phase 3 2010-05-01 The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e., treatment with a single drug) and have inadequate glycemic (blood sugar) control.
NCT01106690 ↗ The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone) Completed Janssen Research & Development, LLC Phase 3 2010-06-01 The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receving treatment with metformin and pioglitazone and have inadequate glycemic (blood sugar) control.
NCT01137812 ↗ The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial) Completed Janssen Research & Development, LLC Phase 3 2010-07-01 The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
NCT01273571 ↗ A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 2010-12-01 The purpose of the study is to investigate the potential interaction between multiple oral doses of canagliflozin and a single oral dose of metformin in healthy adult volunteers.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Canagliflozin; Metformin Hydrochloride

Condition Name

Condition Name for Canagliflozin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 18
Healthy 16
Healthy Volunteers 4
Type 2 Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Canagliflozin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus 26
Diabetes Mellitus, Type 2 25
Non-alcoholic Fatty Liver Disease 3
Liver Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Canagliflozin; Metformin Hydrochloride

Trials by Country

Trials by Country for Canagliflozin; Metformin Hydrochloride
Location Trials
United States 250
Canada 25
India 15
Mexico 11
United Kingdom 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Canagliflozin; Metformin Hydrochloride
Location Trials
Arizona 17
Texas 13
Florida 13
California 13
Louisiana 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Canagliflozin; Metformin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Canagliflozin; Metformin Hydrochloride
Clinical Trial Phase Trials
Phase 4 10
Phase 3 9
Phase 2 3
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Canagliflozin; Metformin Hydrochloride
Clinical Trial Phase Trials
Completed 42
Recruiting 4
Not yet recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Canagliflozin; Metformin Hydrochloride

Sponsor Name

Sponsor Name for Canagliflozin; Metformin Hydrochloride
Sponsor Trials
Janssen Research & Development, LLC 31
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 5
University of Leicester 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Canagliflozin; Metformin Hydrochloride
Sponsor Trials
Industry 42
Other 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.